Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| CO2 fractional laser(ACUPULSE,Lumenis) | Experimental | gradually withdrawn from inside to outside of vaginal. with CO2 fractional laser therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%,ACUPULSE,Lumenis) ,once a month for a total of 3 times .CO2 fractional laser stimulates fibroblasts to synthesize and secrete collagen fibers, elastic fibers, reticular fibers and organic matrix through dot exfoliation and thermal stimulation, thus thickening the vaginal wall and achieving long-term vaginal tightening effect. The heat effect of CO2 laser can stimulate vasodilation, increase blood flow, increase cell oxidation and nutrients, increase mitochondrial ATP release, activate cell function, enhance vaginal mucosal secretion, enhance secretion, normalize vaginal PH and bacterial flora, and then reduce the probability of gynecological infection. |
|
| before treatment | No Intervention | the patient did not receive laser treatment |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| CO2 fractional laser(ACUPULSE,Lumenis) | Device | gradually withdrawn from inside to outside of vaginal. with Acupulse Femtouch mode therapy ( hexagonal spot , 10-12.5m J/cm2 , density 5-15%) ,once a month for a total of 3 times |
| Measure | Description | Time Frame |
|---|---|---|
| female sexual function FSFI score(Female Sexual Function Index ) | Questionnaire content involving sexual activity, intercourse, sexual stimulation, sexual desire or sexual interest, sexual excitement or sexual arousal, evaluation of female sexual function, questionnaire score ≤ 26.55 is considered female sexual dysfunction | Changes from preoperative to 1 year after initial treatment |
| urinary incontinence questionnaire short form assessment | Evaluate urinary incontinence questionnaire short form assessment | Changes from preoperative to 1 year after initial treatment |
| VHIS score in vaginal environment | Comprehensive evaluation of vaginal status by vulvar status, internal PH value, vaginal elasticity, guided endocrine secretion, and vaginal moistness | Changes from preoperative to 1 year after initial treatment |
| vaginal pressure VTI data detection | Evaluate vaginal pressure by VTI data detection | Changes from preoperative to 1 year after initial treatment |
| pelvic floor magnetic resonance MRI plain | Measure tissue structures in the pelvis | Changes from preoperative to 1 year after initial treatment |
| scantransvaginal ultrasound | Measure the structures of the vagina | Changes from preoperative to 1 year after initial treatment |
| histopathological biopsy |
| Measure | Description | Time Frame |
|---|---|---|
| patient satisfaction assessment | Patient satisfaction: Very satisfied, satisfied, average, dissatisfied, very dissatisfied | Changes from preoperative to 1 year after initial treatment |
| VAS Pain Assessment(Immediately after Treatment) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gang Wang | Dermatology Derpartment of Xijing Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Dermatology Derpartment of Xijing Hospital | Xi'an | Shaanxi | 710032 | China |
Not provided
| ID | Term |
|---|---|
| D014550 | Urinary Incontinence, Stress |
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
5 cases were randomly selected for histopathological biopsy |
| Changes before and 1month after treatment |
VAS pain scoring criteria (0-10 points): 0 points: no pain; less than 3 points: mild pain, can tolerate; 4 points 1-6 points: patients with pain and affect sleep, can still tolerate; 7 points-10 points : The patient has increasing pain, and the pain is intolerable
| 3 months |
| D005261 |
| Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |